WJOG5208L_2B | R Documentation |
Kaplan-Meier digitized data from WJOG5208L, figure 2B (PMID 26522337). A reported sample size of 355 for a primary endpoint of OS in lung cancer.
WJOG5208L_2B
A data frame of 349 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (cisplatin_docetaxel, nedaplatin_docetaxel) | |
Shukuya T, Yamanaka T, Seto T, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Lancet Oncol 2015; 16: 1630–8.
summary(WJOG5208L_2B)
kmplot(WJOG5208L_2B)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.